المؤلفون: Vieira, Gonçalo, Custódio, Ana, Rodrigues, Catarina, Júlia, Érica, Gomes, Johana, Loureiro, Fernanda

مصطلحات موضوعية: Enfermagem, Saúde infantil

الوصف: Poster apresentado nas III Jornadas Científicas Universitárias e Politécnicas da Egas Moniz, Monte de Caparica, 01-02-2023 ; N/A

العلاقة: http://hdl.handle.net/10400.26/50619Test

الإتاحة: http://hdl.handle.net/10400.26/50619Test

المؤلفون: La-Salvia, Anna, Lens-Pardo, Alberto, López-López, Ángel, Carretero-Puche, Carlos, Capdevila, Jaume, Benavent, Marta, Jiménez-Fonseca, Paula, Castellano, Daniel, Alonso, Teresa, Teule, Alexandre, Custodio, Ana, Tafuto, Salvatore, La Casta, Adelaida, Spada, Francesca, López-Gonzalvez, Ángeles, Gil-Calderón, Beatriz, Espinosa-Olarte, Paula, Barbas, Coral, García-Carbonero, Rocío, Soldevilla, Beatriz

المساهمون: Pfizer, Agencia Estatal de Investigación (España), Ministerio de Ciencia, Innovación y Universidades (España), Comunidad de Madrid, Instituto de Salud Carlos III, European Commission, Asociación Española Contra el Cáncer, Benavent, Marta, Soldevilla, Beatriz, Consejo Superior de Investigaciones Científicas https://ror.org/02gfc7t72Test

مصطلحات موضوعية: Neuroendocrine tumors, Metabolomics, Plasma metabolites, Prognostic biomarker

الوصف: © The Author(s) 2023. Published by Oxford University Press on behalf of European Society of Endocrinology. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0Test/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com ; [Objective] Metabolic profiling is a valuable tool to characterize tumor biology but remains largely unexplored in neuroendocrine tumors (NETs). Our aim was to comprehensively assess the metabolomic profile of NETs and identify novel prognostic biomarkers and dysregulated molecular pathways. ; [Design and Methods] Multiplatform untargeted metabolomic profiling (GC-MS, CE-MS, and LC-MS) was performed in plasma from 77 patients with G1-2 extra-pancreatic NETs enrolled in the AXINET trial (NCT01744249) (study cohort) and from 68 non-cancer individuals (control). The prognostic value of each differential metabolite (n = 155) in NET patients (P < .05) was analyzed by univariate and multivariate analyses adjusted for multiple testing and other confounding factors. Related pathways were explored by Metabolite Set Enrichment Analysis (MSEA) and Metabolite Pathway Analysis (MPA). ; [Results] Thirty-four metabolites were significantly associated with progression-free survival (PFS) (n = 16) and/or overall survival (OS) (n = 27). Thirteen metabolites remained significant independent prognostic factors in multivariate analysis, 3 of them with a significant impact on both PFS and OS. Unsupervised clustering of these 3 metabolites stratified patients in 3 distinct prognostic groups (1-year PFS of 71.1%, 47.7%, and 15.4% (P = .012); 5-year OS of 69.7%, 32.5%, and 27.7% (P = .003), respectively). The MSEA and MPA of the 13-metablolite signature identified methionine, porphyrin, and tryptophan metabolisms as the 3 most relevant dysregulated pathways associated ...

وصف الملف: application/pdf

العلاقة: #PLACEHOLDER_PARENT_METADATA_VALUE#; info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/RTI2018-095166-B-I00/ES/MAS ALLA DE LA HUELLA METABOLICA: HACIA LA IDENTIFICACION EXHAUSTIVA EN METABOLOMICA/; B2017/BMD-3751/NOVELREN-CM; PEJD-2019-PRE/BMD-17058; PEJD-2016-PRE/BMD-2666; PEJD-2017-PRE/BMD-4981; Publisher's version; The underlying dataset has been published as supplementary material of the article in the publisher platform at https://doi.org/10.1093/ejendo/lvad160Test; https://doi.org/10.1093/ejendo/lvad160Test; Sí; European Journal of Endocrinology 190(1): 62-74 (2024); http://hdl.handle.net/10261/360512Test

الإتاحة: https://doi.org/10.1093/ejendo/lvad160Test
http://hdl.handle.net/10261/360512Test

المؤلفون: Silva, Everton J., Custódio, Ana Luísa

مصطلحات موضوعية: Mathematics - Optimization and Control

الوصف: Direct Multisearch (DMS) is a well-established class of methods for multiobjective derivative-free optimization, where constraints are addressed by an extreme barrier approach, only evaluating feasible points. In this work, we propose a filter approach, combined with an inexact feasibility restoration step, to address constraints in the DMS framework. The filter approach treats feasibility as an additional component of the objective function, avoiding the computation of penalty parameters or Lagrange multipliers. The inexact restoration step attempts to generate new feasible points, contributing to prioritize feasibility, a requirement for the good performance of any filter approach. Theoretical results are provided, analyzing the different types of sequences of points generated by the new algorithm, and numerical experiments on a set of nonlinearly constrained biobjective problems are reported, stating the good algorithmic performance of the proposed approach.

العلاقة: http://arxiv.org/abs/2401.08277Test

الإتاحة: http://arxiv.org/abs/2401.08277Test

المؤلفون: Custódio, Ana Luisa, Fortes Escalona, Miguel Ángel, Sajo-Castelli, A. M.

الوصف: In this paper we handle the problem of filling the hole in the graphic of a surface by means of a patch that joins the original surface with C1-smoothness and fulfills an additional non-linear geometrical constraint regarding its area or its mean curvature at some points. Furthermore, we develop a technique to estimate the optimum area that the filling patch is expected to have that will allow us to determine optimum filling patches by means of a system of linear and quadratic equations. We present several numerical and graphical examples showing the effectiveness of the proposed method. ; Funding for open access publishing: Universidad de Granada/CBUA ; National funds through the FCT - Fundação para a Ciência e a Tecnologia ; Projects UIDB/00297/2020 and UIDP/00297/2020 (Center for Mathematics and Applications)

العلاقة: Custódio, A.L., Fortes, M.A. & Sajo-Castelli, A.M. Filling holes under non-linear constraints. Comp. Appl. Math. 42, 72 (2023). [https://doi.org/10.1007/s40314-023-02210-3Test]; https://hdl.handle.net/10481/80058Test

الإتاحة: https://doi.org/10.1007/s40314-023-02210-3Test
https://hdl.handle.net/10481/80058Test

المؤلفون: Salvia, Anna La, Lens Pardo, Alberto, López López, Angel, Carretero Puche, Carlos, Capdevila, Jaume, Benavent, Marta, Jiménez Fonseca, Paula, Castellano, Daniel, Alonso, Teresa, Teule, Alexandre, Custodio, Ana, Tafuto, Salvatore, Casta, Adelaida La, Spada, Francesca, Lopez Gonzalvez, Angeles, Gil Calderon, Beatriz, Espinosa Olarte, Paula, Barbas, Coral, Garcia Carbonero, Rocio, Soldevilla, Beatriz

المصدر: Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

مصطلحات موضوعية: Triptòfan, Porfirines, Tryptophan, Porphyrins

الوصف: Objective: Metabolic profiling is a valuable tool to characterize tumor biology but remains largely unexplored in neuroendocrine tumors (NETs). Our aim was to comprehensively assess the metabolomic profile of NETs and identify novel prognostic biomarkers and dysregulated molecular pathways.Design and Methods: Multiplatform untargeted metabolomic profiling (GC-MS, CE-MS, and LC-MS) was performed in plasma from 77 patients with G1-2 extra-pancreatic NETs enrolled in the AXINET trial (NCT01744249) (study cohort) and from 68 non-cancer individuals (control). The prognostic value of each differential metabolite (n = 155) in NET patients (P < .05) was analyzed by univariate and multivariate analyses adjusted for multiple testing and other confounding factors. Related pathways were explored by Metabolite Set Enrichment Analysis (MSEA) and Metabolite Pathway Analysis (MPA).Results: Thirty-four metabolites were significantly associated with progression-free survival (PFS) (n = 16) and/or overall survival (OS) (n = 27). Thirteen metabolites remained significant independent prognostic factors in multivariate analysis, 3 of them with a significant impact on both PFS and OS. Unsupervised clustering of these 3 metabolites stratified patients in 3 distinct prognostic groups (1-year PFS of 71.1%, 47.7%, and 15.4% (P = .012); 5-year OS of 69.7%, 32.5%, and 27.7% (P = .003), respectively). The MSEA and MPA of the 13-metablolite signature identified methionine, porphyrin, and tryptophan metabolisms as the 3 most relevant dysregulated pathways associated with the prognosis of NETs.Conclusions: We identified a metabolomic signature that improves prognostic stratification of NET patients beyond classical prognostic factors for clinical decisions. The enriched metabolic pathways identified reveal novel tumor vulnerabilities that may foster the development of new therapeutic strategies for these patients.

وصف الملف: 13 p.; application/pdf

العلاقة: Reproducció del document publicat a: https://doi.org/10.1093/ejendo/lvad160Test; European Journal of Endocrinology, 2023, vol. 190, num. 1, p. 62-74; https://doi.org/10.1093/ejendo/lvad160Test; http://hdl.handle.net/2445/207657Test

الإتاحة: https://doi.org/10.1093/ejendo/lvad160Test
http://hdl.handle.net/2445/207657Test

المؤلفون: Capdevila, Jaume, Hernando, Jorge, Teulé Vega, Àlex, Lopez, C., Garcia Carbonero, R., Benavent, M., Custodio, Ana, García Alvárez, Alejandro, Cubillo, A., Alonso, V., Carmona Bayonas, Alberto, Alonso Gordoa, Teresa, Crespo, Guillermo, Jiménez Fonseca, P., Blanco, M., Viudez, A., Casta, A. la, Sevilla, I., Segura, A., Llanos, M., Landolfi, Stefania, Nuciforo, Paolo, Manzano Mozo, José Luis

المصدر: Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

مصطلحات موضوعية: Neuroendocrinologia, Tumors, Neuroendocrinology

الوصف: Single immune checkpoint blockade has shown limited activity in patients with neuroendocrine neoplasms (NENs). Here the authors report the results of a phase II clinical trial of durvalumab (anti-PD-L1) and tremelimumab (anti CTLA-4) in patients with advanced NENs of gastroenteropancreatic and lung origin. Single immune checkpoint blockade in advanced neuroendocrine neoplasms (NENs) shows limited efficacy; dual checkpoint blockade may improve treatment activity. Dune (NCT03095274) is a non-randomized controlled multicohort phase II clinical trial evaluating durvalumab plus tremelimumab activity and safety in advanced NENs. This study included 123 patients presenting between 2017 and 2019 with typical/atypical lung carcinoids (Cohort 1), G1/2 gastrointestinal (Cohort 2), G1/2 pancreatic (Cohort 3) and G3 gastroenteropancreatic (GEP) (Cohort 4) NENs; who progressed to standard therapies. Patients received 1500 mg durvalumab and 75 mg tremelimumab for up to 13 and 4 cycles (every 4 weeks), respectively. The primary objective was the 9-month clinical benefit rate (CBR) for cohorts 1-3 and 9-month overall survival (OS) rate for Cohort 4. Secondary endpoints included objective response rate, duration of response, progression-free survival according to irRECIST, overall survival, and safety. Correlation of PD-L1 expression with efficacy was exploratory. The 9-month CBR was 25.9%/35.5%/25% for Cohorts 1, 2, and 3 respectively. The 9-month OS rate for Cohort 4 was 36.1%, surpassing the futility threshold. Benefit in Cohort 4 was observed regardless of differentiation and Ki67 levels. PD-L1 combined scores did not correlate with treatment activity. Safety profile was consistent with that of prior studies. In conclusion, durvalumab plus tremelimumab is safe in NENs and shows modest survival benefit in G3 GEP-NENs; with one-third of these patients experiencing a prolonged OS.

وصف الملف: 8 p.; application/pdf

العلاقة: Reproducció del document publicat a: https://doi.org/10.1038/s41467-023-38611-5Test; Nature Communications, 2023, vol. 14, num. 1; https://doi.org/10.1038/s41467-023-38611-5Test; http://hdl.handle.net/2445/200909Test

الإتاحة: https://doi.org/10.1038/s41467-023-38611-5Test
http://hdl.handle.net/2445/200909Test

المؤلفون: Carmona-Bayonas, Alberto, Custodio, Ana, García Carbonero, Rocío, Capdevila Castillon, Jaume, Alonso-Gordoa, Teresa, Grande, Enrique

المساهمون: Institut Català de la Salut, Capdevila Castillón J Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Alonso Gordoa T Servicio de Oncología Médica, Hospital Universitario Ramón y Cajal, Madrid, Spain. Carmona Bayonas A Servicio de Oncología Médica, Hospital Universitario Morales Meseguer, Murcia, Spain. Custodio Carretero A Servicio de Oncología Médica, Hospital Universitario La Paz, Madrid, Spain. García-Carbonero R Servicio de Oncología Médica, Hospital Universitario 12 de Octubre, Madrid, Spain. Grande Pulido E Servicio de Oncología Médica, MD Anderson Cancer Center, Madrid, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Tumors neuroendocrins - Tractament, Bronquis - Càncer - Tractament, DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonal::Neuroectodermal Tumors::Neuroendocrine Tumors, DISEASES::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms, HEALTH CARE::Health Services Administration::Patient Care Management::Disease Management, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::tumores neuroendocrinos, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios, ATENCIÓN DE SALUD::administración de los servicios de salud::gestión de la atención al paciente::tratamiento de las enfermedades

الوصف: Diagnosis; Neuroendocrine; Therapy ; Diagnòstic; Neuroendocrí; Teràpia ; Diagnóstico; Neuroendocrino; Terapia ; Neuroendocrine neoplasms (NENs) are a heterogeneous family of tumors of challenging diagnosis and clinical management. Their incidence and prevalence continue to rise mainly due to an improvement on diagnostic techniques and awareness. Earlier detection, along with steadfast improvements in therapy, has led to better prognosis over time for advanced gastrointestinal and pancreatic neuroendocrine tumors. The aim of this guideline is to update evidence-based recommendations for the diagnosis and treatment of gastroenteropancreatic and lung NENs. Diagnostic procedures, histological classification, and therapeutic options, including surgery, liver-directed therapy, peptide receptor radionuclide therapy, and systemic hormonal, cytotoxic or targeted therapy, are reviewed and discussed, and treatment algorithms to guide therapeutic decisions are provided.

وصف الملف: application/pdf

العلاقة: Clinical and Translational Oncology;25; https://doi.org/10.1007/s12094-023-03205-6Test; Capdevila Castillón J, Alonso Gordoa T, Carmona Bayonas A, Custodio Carretero A, García-Carbonero R, Grande Pulido E, et al. SEOM-GETNE clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2022). Clin Transl Oncol. 2023 Sep;25:2692–706.; https://hdl.handle.net/11351/10244Test; 000990922300001

الإتاحة: https://doi.org/10.1007/s12094-023-03205-6Test
https://hdl.handle.net/11351/10244Test

المؤلفون: Martínez-Pérez, Daniel, Viñal, David, Peña-Lopez, Jesús, Jiménez-Bou, Diego, Ruiz-Gutiérrez, Iciar, Martínez-Recio, S., Alameda-Guijarro, María, Rueda-Lara, A., Martin-Montalvo, G., Ghanem, Ismael, Custodio, Ana Belén, Trilla-Fuertes, Lucía, Gámez, Ángelo, Barbáchano, Antonio, Rodríguez-Cobos, Javier, Bustamante-Madrid, Pilar, Fernández-Barral, Asunción, Burgos, Aurora, Prieto-Nieto, María Isabel, Pastrián, L. G., González-Sancho, José Manuel, Muñoz Terol, Alberto, Feliu, Jaime, Rodríguez-Salas, Nuria

المساهمون: Instituto de Salud Carlos III, European Commission, Comunidad de Madrid

مصطلحات موضوعية: Early-onset colorectal cancer, COVID-19 pandemic, Prognosis

الوصف: [Background]: The rising incidence of colorectal cancer (CRC) among young patients is alarming. We aim to characterize the clinico-pathological features and outcomes of patients with early-onset CRC (EOCRC), as well as the impacts of COVID-19 pandemic. ; [Methods]: We included all patients with pathologically confirmed diagnoses of CRC at Hospital Universitario La Paz from October 2016 to December 2021. The EOCRC cut-off age was 50 years old. ; [Results]: A total of 1475 patients diagnosed with CRC were included, eighty (5.4%) of whom had EOCRC. Significant differences were found between EOCRC and later-onset patients regarding T, N stage and metastatic presentation at diagnosis; perineural invasion; tumor budding; high-grade tumors; and signet ring cell histology, with all issues having higher prevalence in the early-onset group. More EOCRC patients had the RAS/ BRAF wild type. Chemotherapy was administered more frequently to patients with EOCRC. In the metastatic setting, the EOCRC group presented a significantly longer median OS. Regarding the COVID-19 pandemic, more patients with COVID-19 were diagnosed with metastatic disease (61%) in the year after the lockdown (14 March 2020) than in the pre-pandemic EOCRC group (29%). ; [Conclusions]: EOCRC is diagnosed at a more advanced stage and with worse survival features in localized patients. More patients with EOCRC were diagnosed with metastatic disease in the year after the COVID-19 pandemic lockdown. The long-term consequences of COVID-19 are yet to be determined. ; The work in the authors’ laboratory is funded by the Instituto de Salud Carlos III (ISCIII) and the Fondo Europeo de Desarrollo Regional (FEDER) (ICI20/00057, CIBERONC/CB16/12/00273, and CIBERONC/CB16/12/00398), as well as the Comunidad de Madrid (S2022/BMD-7212). ; Peer reviewed

وصف الملف: application/pdf

العلاقة: #PLACEHOLDER_PARENT_METADATA_VALUE#; S2022/BMD-7212; Cancers; Publisher's version; The underlying dataset has been published as supplementary material of the article in the publisher platform at 10.3390/cancers15174242; https://doi.org/10.3390/cancers15174242Test; Sí; Cancers 15(17): 4242 (2023); http://hdl.handle.net/10261/349411Test; http://dx.doi.org/10.13039/501100004587Test; http://dx.doi.org/10.13039/501100000780Test; http://dx.doi.org/10.13039/100012818Test; 2-s2.0-85170355202; https://api.elsevier.com/content/abstract/scopus_id/85170355202Test

الإتاحة: https://doi.org/10.3390/cancers1517424210.13039/50110000458710.13039/50110000078010.13039/100012818Test
http://hdl.handle.net/10261/349411Test
https://api.elsevier.com/content/abstract/scopus_id/85170355202Test

المؤلفون: Ligero, Marta, Hernando, Jorge, Delgado, Eric, Garcia-Ruiz, Alonso, Merino-Casabiel, Xavier, Ibrahim, Toni, Fazio, Nicola, Lopez, Carlos, Teulé, Alexandre, Valle, Juan W., Tafuto, Salvatore, Custodio, Ana, Reed, Nicholas, Raderer, Markus, Grande, Enrique, Garcia-Carbonero, Rocio, Jimenez-Fonseca, Paula, Garcia-Alvarez, Alejandro, Escobar, Manuel, Casanovas, Oriol, Capdevila, Jaume, Perez-Lopez, Raquel

المساهمون: PERIS-Predoctoral fellowship, CRIS Foundation Talent Award, Instituto de Salud Carlos III-Investigacion en Salud, Prostate Cancer Foundation

المصدر: BJC Reports ; volume 1, issue 1 ; ISSN 2731-9377

الوصف: Background More accurate predictive biomarkers in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are needed. This study aims to investigate radiomics-based tumour phenotypes as a surrogate biomarker of the tumour vasculature and response prediction to antiangiogenic targeted agents in patients with GEP-NETs. Methods In this retrospective study, a radiomics signature was developed in patients with GEP-NETs and liver metastases receiving lenvatinib. Patients were selected from the multicentre phase II TALENT trial (NCT02678780) (development cohort). Radiomics variables were extracted from liver metastases in the pre-treatment CT-scans and selected using LASSO regression and minimum redundancy maximum relevance (mRMR). Logistic regression and Cox proportional-hazards models for radiomics and combined radiomics with clinical data were explored. The performance of the models was tested in an external cohort of patients treated with sunitinib (test cohort). Associations between the radiomics score and vascularisation factors in plasma were studied using hierarchical clustering and Mann–Whitney U test. Results A total of 89 patients were included in the study, 408 liver metastases were analysed. The CT-based radiomics signature was associated with clinical benefit in the development (training and validation sets) and test cohorts (AUC 0.75 [0.66–0.90], 0.67 [0.49–0.92] and 0.67 [0.43–0.91], respectively). The combined radiomics-clinical signature (including the radiomics score, Ki-67 index and primary tumour site) improved on radiomics-only signature performance (AUC 0.79 [95% CI 0.64–0.93]; p < 0.001). A higher radiomics score indicated longer progression-free survival (hazard ration of 0.11 [0.03–0.45]; p = 0.002) and was associated with vascularisation factors ( p = 0.01). Conclusions Radiomics-based phenotypes can provide valuable information about tumour characteristics, including the vasculature, that are associated with response to antiangiogenics. Clinical trial registration ...

الإتاحة: https://doi.org/10.1038/s44276-023-00010-0Test
https://www.nature.com/articles/s44276-023-00010-0.pdfTest
https://www.nature.com/articles/s44276-023-00010-0Test

المؤلفون: Mitjavila, Mercedes, Jimenez-Fonseca, Paula, Belló, Pilar, Pubul, Virginia, Percovich, Juan Carlos, Garcia-Burillo, Amparo, Hernando, Jorge, Arbizu, Javier, Rodeño, Emilia, Estorch, Montserrat, Llana, Belén, Castellón, Maribel, García-Cañamaque, Lina, Gajate, Pablo, Riesco, Maria Carmen, Miguel, Maria Begoña, Balaguer-Muñoz, David, Custodio, Ana, Cano, Juana María, Repetto, Alexandra, Garcia-Alonso, Pilar, Muros, Maria Angustias, Vercher-Conejero, Jose Luis, Carmona-Bayonas, Alberto

المساهمون: Novartis Farmacéutica

المصدر: European Journal of Nuclear Medicine and Molecular Imaging ; volume 50, issue 8, page 2486-2500 ; ISSN 1619-7070 1619-7089

مصطلحات موضوعية: Radiology, Nuclear Medicine and imaging, General Medicine

الوصف: Background Peptide receptor radionuclide therapy (PRRT) is one of the most promising therapeutic strategies in neuroendocrine neoplasms (NENs). Nevertheless, its role in certain tumor sites remains unclear. This study sought to elucidate the efficacy and safety of [ 177 Lu]Lu-DOTATATE in NENs with different locations and evaluate the effect of the tumor origin, bearing in mind other prognostic variables. Advanced NENs overexpressing somatostatin receptors (SSTRs) on functional imaging, of any grade or location, treated at 24 centers were enrolled. The protocol consisted of four cycles of 177 Lu-DOTATATE 7.4 GBq iv every 8 weeks (NCT04949282). Results The sample comprised 522 subjects with pancreatic (35%), midgut (28%), bronchopulmonary (11%), pheochromocytoma/ paraganglioma (PPGL) (6%), other gastroenteropancreatic (GEP) (11%), and other non-gastroenteropancreatic (NGEP) (9%) NENs. The best RECIST 1.1 responses were complete response, 0.7%; partial response, 33.2%; stable disease, 52.1%; and tumor progression, 14%, with activity conditioned by the tumor subtype, but with benefit in all strata. Median progression-free survival (PFS) was 31.3 months (95% CI, 25.7–not reached [NR]) in midgut, 30.6 months (14.4-NR) in PPGL, 24.3 months (18.0-NR) in other GEP, 20.5 months (11.8-NR) in other NGEP, 19.8 months (16.8–28.1) in pancreatic, and 17.6 months (14.4–33.1) in bronchopulmonary NENs. [ 177 Lu]Lu-DOTATATE exhibited scant severe toxicity. Conclusion This study confirms the efficacy and safety of [ 177 Lu]Lu-DOTATATE in a wide range of SSTR-expressing NENs, regardless of location, with clinical benefit and superimposable survival outcomes between pNENs and other GEP and NGEP tumor subtypes different from midgut NENs.

الإتاحة: https://doi.org/10.1007/s00259-023-06166-8Test